British Life Science Specialists to Provide Nationwide Support for Overseas Companies Establishing UK Business Operations
August 31, 2017-A group of specialist providers of life sciences services (including BG Healthcare, Clinical Professionals, Illingworth Research Group, Roboleo and Co., and TRAC Services), announce an alliance, The Health Science Business Gateway (HSBG), to provide complete and comprehensive support for overseas companies which are looking to establish business operations in the UK.
The members of the HSBG already work with a number of shared clients. The new venture will see them working more closely together and with affiliated organizations to “unlock access” to the UK life science environment, and help promote inward investment to the UK. It provides an initial single point of contact to access a comprehensive network of businesses for specialist advice and support in key areas such as Regulation, R&D, Market Development, Technology Assessment, NHS Access, Talent Landscape, and Corporate Law.
Dr Mark Edwards, Chairman of the HSBG commented, “It can be difficult to find the correct types of ‘hands-on’ specialist support to establish and grow in a foreign country. HSBG makes that task easier by acting as the first ‘National Chaperone’ for the UK’s life sciences ecosystem. All its members have been brought together by a collective respect for each other’s expertise, knowledge, and a shared ethos to deliver the outcomes companies seek on-time, on-target, and on-budget.”
Yvette Cleland, CEO of Clinical Professionals commented, “Earlier this year, EY announced that the UK is still first for foreign direct investment (FDI) in Europe. The Department of International Trade (DIT) stated the UK attracted over 2,200 new inward investment projects in 2016/17 leading to 107,000 new roles being created. DIT has been at the forefront of 80% of these projects. With the launch today of the ‘Life Sciences Strategy’ and as the DIT continues to drive FDI within life sciences, it is essential that we offer a complementary service that acts as a nationwide gateway for investors wishing to investigate the UK as a destination of choice for their expanding life sciences business. We must remain at the forefront of investor choice so we can continue to compete effectively on the world stage and maintain our place as a top European destination for life sciences.”
More information about HSBG can be obtained from Dr Mark Edwards via info@hsbgateway.com or please visit www.hsbgateway.com.
About HSBG’s Founding Members
BG Healthcare is an experienced Healthcare consultancy, market advisor and leading expert in business strategy and development.
Clinical Professionals is Europe’s leading Life Science staffing business, including an award-winning Graduate Academy, industry analytics and knowledgeable expert recruitment.
Illingworth Research Group is a Clinical Research Organization (CRO) providing a wide range of clinical development services including on and off-site research nursing and medical photography services to life science businesses.
Roboleo & Co is an independent consultancy delivering innovative Market Access solutions within the Pharmaceutical and Med-tech market sectors.
TRAC is an independent regulatory affairs consultancy dedicated to serving the global pharmaceutical industry.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
